الفهرس 
Introduction and Review of LiteratureOnly 14 pages are availabe for public view
 |  | from | 177 |  |  |
| | | from | 177 | | |
Abstract
Hepatocellular carcinoma (HCC) is the leading lethal common malignancy worldwide. Serum markers, various imaging modalities and histological analysis are diagnostic techniques for HCC. A useful diagnostic biomarker for HCC is Glypican-3 (GPC3). This paper evaluates this marker depending on HCC rat model. Immunohistochemical, ELISA and RT-PCR techniques were used to perform histopathological, biochemical and molecular evaluation of alpha-fetoprotein (AFP) and GPC3. Levels of serum GPC3 and AFP showed significant increase in HCC compared to degenerating, precancerous and control groups. On one hand, the sensitivity, specificity and accuracy of the control versus either degenerating or precancerous groups for serum GPC3 are higher than those for AFP. On the other hand, the control versus HCC group has the same sensitivity, specificity and accuracy for both markers. GPC3 and AFP using RT-PCR were higher in precancerous and cancerous but degenerating group have less GPC3 and AFP using RT-PCR. Combination of AFP and GPC3 has very high NPV (100%) to differentiate either degenerated nodules or dysplastic nodules from HCC in terms of regression analysis. The bottom line is that HCC diagnostic accuracy is increasing by using GPC3, which is an acceptable serum biomarker (at serum and molecular levels). The sensitivity for diagnosis of HCC is escalated by the simultaneous determination of GPC3 and AFP.